I-SPY
Richard Lee
- OPEN TO ACCRUAL
trials found matching your search:
Displaying 20 of 282 Results
PhII EvalSafTolerabEfficPK&Immu AZD0901 Monothe&Combw/AntiCa Agen Partic w/AdvSolTuExpresClaudin18.2
Farshid Dayyani
- OPEN TO ACCRUAL
PhII/III Rad w/Cisplatin 100mg/m2Ever3WeekVsRadw/WeekCisplatin400mg/m2 Pa w/LocoregionallAdvSCCHN
Shirin Attarian
- OPEN TO ACCRUAL
PhIIIAdjuvV940mRNA4157+PembrolizumabVSAdjuvPlacebo+Pembrow/ResectStageII IIIAIIIB N2NSCLC V940-002
Hari Keshava
- OPEN TO ACCRUAL
PROJECT-BARI
Kishore Gadde
- OPEN TO ACCRUAL
Phase 3 Study of ALXN2220 versus Placebo in Adults with ATTR-CM
Roxana Ghashghaei
- OPEN TO ACCRUAL
MAP
Brian Hitt
- OPEN TO ACCRUAL
PhI/II FirstInHuman Study DF9001 Comb w/Nivolumab Pa w/Solid Tumors Selected Indications
Jennifer Brooke Valerin
- OPEN TO ACCRUAL
Caffeine Use in the Management of Preterm Infants
Cherry Uy
- OPEN TO ACCRUAL
Evaluate Satralizumab as Monotherapy or in Addition to Baseline Therapy in Patients with MOGAD
Michael Sy
- OPEN TO ACCRUAL
Impact of Sodium Bicarbonate on 24-hour Urine Parameters in Hypocitriuric and Uric Acid Stone Former
Ralph Victor Clayman
- OPEN TO ACCRUAL
PhII TrialDurvalumab w/Gemcitabine&CisplatinNeoadj The forHighRisk ResecIntrahepic CholangioCa
Zeljka Jutric
- OPEN TO ACCRUAL
Relationship bw Image-derivFeatures of Intraoperative ICGVisualiz of NVBs during RARP&FunctionalOutc
David Lee
- OPEN TO ACCRUAL
PhI/Ib FirstInHuman Investig SafeTolerabPharmBiologic&ClinicalActiv DF6215 Pa w/Adv Solid Tu
Jennifer Brooke Valerin
- OPEN TO ACCRUAL
PhII/IIIChem+CetuximabvsChem+BevacizumabvsAtezolizumab+BevacizumabImmCheckPoinInhibRecurMetsH&NCa
Shirin Attarian
- OPEN TO ACCRUAL
PhI Study PolymeraseThetaInhibitor Novobiocin BRCAMutant&Other DNADamageRepair-Deficient SolidTumors
Jennifer Brooke Valerin
- OPEN TO ACCRUAL
Study of efficacy and safety of iptacopan in participants with IC-MPGN
Ramy Hanna
- OPEN TO ACCRUAL
LIBREXIA-STROKE
Jay Shah
- OPEN TO ACCRUAL
Prospect Eval of Efficacy of CMV-TCIP Direct Letermovir Prophylax after Allogen Hemato Cell Transpla
Piyanuch Kongtim
- OPEN TO ACCRUAL
PhII Nivolumab&Ipilimumab w/orw/outCabozantinib Pa w/AdvNasopharyngealCaProgAfterPlatinumTx&Immunthe
Shirin Attarian
- OPEN TO ACCRUAL